Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis

被引:258
|
作者
Lehrke, Michael [1 ]
Becker, Alexander [2 ]
Greif, Martin [2 ]
Stark, Renee [3 ]
Laubender, Ruediger P. [4 ]
von Ziegler, Franz [2 ]
Lebherz, Corinna [2 ]
Tittus, Janine [2 ]
Reiser, Maximilian [5 ]
Becker, Christoph [5 ]
Goeke, Burkhard [1 ]
Leber, Alexander W. [2 ]
Parhofer, Klaus G. [1 ]
Broedl, Uli C. [1 ]
机构
[1] Univ Munich, Dept Internal Med 2, D-81377 Munich, Germany
[2] Univ Munich, Dept Internal Med 1, D-81377 Munich, Germany
[3] Helmholtz Zentrum, Munich, Germany
[4] Univ Munich, Inst Med Informat Biometry & Epidemiol, Munich, Germany
[5] Univ Munich, Dept Radiol, Munich, Germany
关键词
ADIPOKINE; ADIPOCYTE;
D O I
10.1530/EJE-09-0380
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Chemerin is a recently discovered adipokine that regulates adipocyte differentiation and modulates chemotaxis and activation of dendritic cells and macrophages. Given the convergence of adipocyte and macrophage function, chemerin may provide an interesting link between obesity. inflammation and atherosclerosis in humans. We sought to examine the relationship of i) chemerin and markers of inflammation, ii) chemerin and components of the metabolic syndrome. and iii) chemerin and coronary atherosclerotic plaque burden and morphology. Design: Serum chemerin levels were determined in 303 patients with stable typical or atypical chest Pain Who Underwent dual-source multi-slice CT-angiography to exclude coronary artery stenosis. Atherosclerotic plaques were classified its calcified, mixed. or non-calcified. Results: Chemerin levels were highly correlated with high sensitivity C-reactive protein (r=0.44. P<0.0001). interleukin-6 (r=0.18, P=0.002), tumor necrosis factor-alpha. (r=0.24, P<0.0001). resistin (r=0.28. P<0.0001), and leptin r=0.36. P<0.0001) concentrations. Furthermore, chemerin was associated with components of the metabolic syndrome including body mass index (r=0.23, P=0.0002). triglycerides (r=0.29. P<0.0001), HDL-cholesterol (r=-0.18, P=0.003). and hypertension (P<0.0001). In bivariate analysis. chemerin levels were weakly correlated with coronary plaque burden (r=0.16. P=0.006) and the number of non-calcified plaques (r=0.14. P=0.02). These associations, however, were lost after adjusting for established cardiovascular risk factors (odds ratio. OR 1.17, 95%, confidence interval (Cl) 0.97-1.41. P=0.11 for coronary plaque burden: OR 1.06, 95% Cl 0.96-1.17. P=0.22 for non-calcified plaques). Conclusions: Chemerin is strongly associated with markers of inflammation and components of the metabolic syndrome. However, chemerin does not predict coronary, atherosclerosis.
引用
收藏
页码:339 / 344
页数:6
相关论文
共 50 条
  • [21] Chemerin is associated with the metabolic syndrome but is not linked to angiographically determined coronary artery disease
    Saely, C. H.
    Muendlein, A.
    Vonbank, A.
    Geiger, K.
    Rein, P.
    Drexel, H.
    WIENER KLINISCHE WOCHENSCHRIFT, 2012, 124 (15-16) : 563 - 563
  • [22] Quality of life in patients with coronary heart disease: interrelation with components of metabolic syndrome and markers of systemic inflammation
    Bespalova, I. D.
    Kalyuzhin, V. V.
    Medyantsev, Yu. A.
    BYULLETEN SIBIRSKOY MEDITSINY, 2012, 11 (06): : 17 - +
  • [23] Chemerin is Associated with the Metabolic Syndrome but is not Linked to Angiographically Determined Coronary Artery Disease
    Saely, Christoph H.
    Muendlein, Axel
    Vonbank, Alexander
    Geiger, Kathrin
    Rein, Philipp
    Drexel, Heinz
    CIRCULATION, 2012, 126 (21)
  • [24] Chemerin is Associated With the Metabolic Syndrome But is Not Linked to Angiographically Determined Coronary Artery Disease
    Saely, Christoph H.
    Muendlein, Axel
    Vonbank, Alexander
    Rein, Philipp
    Geiger, Kathrin
    Drexel, Heinz
    DIABETES, 2012, 61 : A116 - A117
  • [25] Chemerin is linked to the metabolic syndrome but is not associated with angiographically verified coronary artery disease
    Saely, Christoph H.
    Muendlein, Axel
    Vonbank, Alexander
    Geiger, Kathrin
    Rein, Philipp
    Drexel, Heinz
    WIENER KLINISCHE WOCHENSCHRIFT, 2012, 124 : 5 - 5
  • [26] Chemerin is associated with the metabolic syndrome but is not linked to angiographically determined coronary artery disease
    Saely, C. H.
    Muendlein, A.
    Vonbank, A.
    Geiger, K.
    Rein, P.
    Drexel, H.
    EUROPEAN HEART JOURNAL, 2012, 33 : 888 - 888
  • [27] Matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis: Relation with inflammation and metabolic markers
    Nanni, S
    Melandri, G
    Hanemaaijer, R
    Cervi, V
    Tomasi, L
    Melloni, C
    Tricoci, P
    Branzi, A
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 282A - 283A
  • [28] Roles of the Metabolic Syndrome, HDL Cholesterol, and Coronary Atherosclerosis in Subclinical Inflammation
    Rein, Philipp
    Saely, Christoph H.
    Beer, Stefan
    Vonbank, Alexander
    Drexel, Heinz
    DIABETES CARE, 2010, 33 (08) : 1853 - 1855
  • [29] Roles of the metabolic syndrome, HDL cholesterol, and coronary atherosclerosis in subclinical inflammation
    Rein, Philipp
    Saely, Christoph
    Beer, Stefan
    Vonbank, Alexander
    Boehnel, Christian
    Jankovic, Vlado
    Drexel, Heinz
    WIENER KLINISCHE WOCHENSCHRIFT, 2010, 122 (17-18) : A9 - A9
  • [30] Changes in Markers of Systemic Inflammation Predict Progression Coronary Atherosclerosis in Patients With Abdominal Obesity
    Shreevatsa, Ajai
    Nicholls, Stephen J.
    Wolski, Kathy
    Bayturan, Ozgur
    Lavoie, Andrea
    Uno, Kiyoko
    Despres, Jean-Pierre
    Deanfield, John
    Kastelein, John K.
    Cannon, Christopher P.
    Job, Bernard
    Gaudin, Christophe
    Tuzcu, E. M.
    Nissen, Steve E.
    CIRCULATION, 2009, 120 (18) : S517 - S517